newsfilter
← Latest News
GlobeNewswire·

Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology

  • Eikon Therapeutics announced full-text abstracts for six presentations at the 2026 ASCO Annual Meeting in Chicago starting May 29, 2026.
  • Presentations will cover clinical progress for EIK1001 (TLR7/8 dual-agonist) in non-small cell lung cancer (NSCLC) and advanced melanoma.
  • Updated data will be shared for EIK1003 (PARP1 inhibitor) as a monotherapy or in combination for breast, ovarian, prostate, or pancreatic cancers.
  • Early development progress will be presented for EIK1005, a WRN inhibitor designed for tumors with DNA replication abnormalities.
  • Specific EIK1001 trials include TeLuRide-005 (NSCLC), TeLuRide-006 (melanoma), and TeLuRide-008 (NSCLC with chemotherapy).
  • EIK1003 data includes initial combination results with paclitaxel and updated monotherapy results from the EIK1003-001 Phase 1/2 study.
  • EIK1005 presentations detail a First-in-Human safety study in healthy participants and a Phase 1/2 study in patients with advanced solid tumors.
  • CEO Roger M. Perlmutter stated the data reflects the pipeline breadth with a focus on monotherapy and combination strategies for advanced disease.
  • Eikon is a late-stage clinical biopharmaceutical company utilizing a proprietary single molecule tracking system to develop oncology therapies.
  • The press release includes forward-looking statements regarding future milestones, data readouts, and financial performance subject to various risks.